Global Prostate Cancer Market Set to Witness a CAGR of 10.3% - ResearchAndMarkets.com

DUBLIN--()--The "Prostate Cancer - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

The Global Prostate Cancer market is growing at a CAGR of 10.3% during the forecast period.

Some of the key factors such as improved diagnosis and frequency rates in industrial economies, rapidly growing geriatric population, and the high demand for effective treatments are propelling the market growth. However, high price for treatment, lack of awareness and short accessibility of health care services in the small regions which are hampering the growth of the market.

Based on Therapy, Biologic therapy is a treatment for patients with prostate cancer that involves utilize of existing organisms, substances plagiaristic from living organisms, or laboratory formed versions of living organisms. Biological therapies use diverse ways to rouse the immune system and stop tumor cells from rising. For patients with cancer, biological therapies may be used to treat the cancer itself or the side effects of other cancer treatments.

By Geography, Asia Pacific is expected to exhibit the utmost growth on account of the existence of untapped opportunity in the rising economies such as India and China. As well, rising healthcare expenditure has caused an increase in the implementation of technically advanced commodities, which is likely to boost county market growth.

Some of the key players profiled in the Prostate Cancer Market include Astellas, Inc., AstraZeneca plc, Bristol Myers Squibb (BMS), Johnson & Johnson, NOVARTIS, Sanofi S.A, TOLMAR Inc., Tokai Pharmaceuticals, Progenics Pharmaceuticals Inc., OncoGenex Pharmaceuticals Inc., OncBioMune Pharmaceuticals Inc., Endo Pharmaceuticals, and Bayer Pharma AG.

What the report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Key Topics Covered

1 Executive Summary

2 Preface

3 Market Trend Analysis

3.1 Introduction

3.2 Drivers

3.3 Restraints

3.4 Opportunities

3.5 Threats

3.6 End User Analysis

3.7 Emerging Markets

3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

5 Global Prostate Cancer Market, By Type

5.1 Introduction

5.2 Hormone Sensitive

5.3 Hormone Refractory

6 Global Prostate Cancer Market, By Therapy

6.1 Introduction

6.2 Focal Therapies

6.3 Biologic Therapy

6.4 Cryosurgery

6.5 Immunotherapy

6.5.1 Vaccines

6.6 Therapeutic Vaccines

6.6.1 Provenge (Sipuleucel-T)

6.7 Radiation Therapy

6.7.1 External Beam

6.7.1.1 Stereotactic Body

6.7.1.2 Proton Beam

6.7.1.3 Intensity Modulated

6.7.1.4 3D Conformal

6.7.2 Brachytherapy

6.7.2.1 Temporary

6.7.2.2 Permanent

6.8 Chemotherapy

6.8.1 Vinorelbine

6.8.2 Vinblastine

6.8.3 Taxotere (Docetaxel)

6.8.4 Taxanes

6.8.5 Jevtana (Cabazitaxel)

6.8.6 Etoposide

6.8.7 Cytotoxic Drugs

6.8.8 Carboplatin

6.8.9 Antimetabolites

6.8.10 Anthracyclines

6.8.11 Alkylating Agents

6.9 Surgery

6.9.1 Trans Urethral Resection (TUR)

6.9.2 Radical Prostatectomy

6.9.3 Orchidectomy

6.10 Targeted Therapy

6.10.1 Tyrosine Kinase Inhibitors

6.10.2 Signal Transduction Inhibitor

6.10.3 Monoclonal Antibodies

6.10.4 Apoptosis Inducing Drugs

6.10.5 Angiogenesis Inhibitor

6.11 Bone Metastasis

6.11.1 Zometa (Zoledronic Acid)

6.11.2 Xofigo (Radium 223 Dichloride)

6.11.3 Xgeva (Denosumab)

6.11.4 Alpharadin

6.12 Hormonal Therapy

6.12.1 Aromatase Inhibitors

6.12.2 Estrogen-Receptor Modulators (Serms)

6.12.3 Luteinizing Hormone-Releasing Hormone (LHRH) Analogs

6.12.3.1 Lupron

6.12.3.2 Zoladex

6.12.3.3 Decapeptyl

6.12.3.4 Eligard

6.12.3.5 Vantas

6.12.3.6 Leuplin

6.12.3.7 Trelstar (Triptorelin Pamoate)

6.12.3.8 Firmagon (Degarelix)

6.12.3.9 Casodex (Bicalutamide)

6.12.4 Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists

6.12.4.1 Zytiga

6.12.4.2 Gonax

6.12.4.3 Xtandi (Enzalutamide)

6.12.5 Anti-Androgens

6.12.5.1 Casodex

6.12.5.2 Xtandi or MDV3100

6.12.5.3 Xtandi US or MDV3100

6.12.6 Other Hormonal Therapies

7 Global Prostate Cancer Market, By Diagnostic Technique

7.1 Introduction

7.2 Prostate Specific Antigen Test (PSA)

7.3 Digital Rectal Exam (DRE)

8 Global Prostate Cancer Market, By End User

8.1 Introduction

8.2 Ambulatory Surgical Centers

8.3 Hospitals

8.4 Pharmacies

8.5 Specialty Clinics

8.6 Other End Users

9 Global Prostate Cancer Market, By Geography

12.1 Introduction

12.2 North America

12.3 Europe

12.4 Asia Pacific

12.5 South America

12.6 Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures

10.2 Acquisitions & Mergers

10.3 New Product Launch

10.4 Expansions

10.5 Other Key Strategies

11 Company Profiling

11.1 Astellas, Inc.

11.2 AstraZeneca plc

11.3 Bristol Myers Squibb (BMS)

11.4 Johnson & Johnson

11.5 NOVARTIS

11.6 Sanofi S.A.

11.7 TOLMAR Inc.

11.8 Tokai Pharmaceuticals

11.9 Progenics Pharmaceuticals Inc.

11.10 OncoGenex Pharmaceuticals Inc.

11.11 OncBioMune Pharmaceuticals Inc.

11.12 Endo Pharmaceuticals

11.13 Bayer Pharma AG

For more information about this report visit https://www.researchandmarkets.com/r/fn6ish

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900